Evidence map›Paper›PMID 42086756›Full record

ArticleScientific reports2026

Terminal residues modulate DNA-binding site size and stability of the SSB-like DNA-binding protein Gp13 from bacteriophage Phi11.

Vivek Ratre, Malabika Biswas

Abstract read
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Vivek RatreDepartment of Biological Sciences, Birla Institute of Technology and Science, Pilani K K Birla Goa Campus, NH17B, Zuarinagar, 403726, Goa, India.ORCID http://orcid.org/0000-0002-3347-2886
Malabika BiswasDepartment of Biological Sciences, Birla Institute of Technology and Science, Pilani K K Birla Goa Campus, NH17B, Zuarinagar, 403726, Goa, India. mbiswas@goa.bits-pilani.ac.in.ORCID http://orcid.org/0000-0002-2497-9765

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gp13 is a homodimeric single-stranded DNA-binding protein (SSB) from bacteriophage Phi11, harboring a C-terminal oligonucleotide/oligosaccharide-binding (OB) fold. To study the functional contributions of its terminal regions, a series of N- and C-terminal deletion mutants were generated and characterized using biochemical and biophysical approaches. Deletions in the N-terminal (residues 2-8) and C-terminal (residues 177-184) residues impaired ssDNA binding and reduced the minimal ssDNA binding size from 25 to 20 nucleotides, revealing that both the terminal regions contribute to efficient DNA interaction. Further deletions in the N-terminus abolished DNA binding, highlighting the potential role of residues R6-E12 in ssDNA binding. Size-exclusion chromatography showed that most mutants retained their dimeric state, suggesting that the dimerization domain lies outside Gp13's terminal residues. Circular dichroism and intrinsic fluorescence analyses revealed localized secondary and tertiary changes in the mutants correlating with binding strength. In addition, Gp13 was found to associate with Staphylococcus aureus RecA in pull-down assays, suggesting a potential interaction between Phi11 SSB and host DNA recombination machinery. Together, these results elucidate the role of terminal residues of Gp13 in influencing the structure and ssDNA- binding properties of the protein.

Indexed as

BacteriophagesDNA-Binding ProteinsViral ProteinsBinding SitesDNA, Single-StrandedProtein BindingProtein MultimerizationDNA-Binding ProteinsDNA, Single-StrandedViral ProteinsAcidic tailBacteriophage Phi11DNA bindingEMSAOB-foldPXXP motif

Identifiers

PMID42086756
PMCPMC13333961

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.